
Opinion|Videos|August 5, 2024
Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies
Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.
Advertisement
Video content above is prompted by the following question(s):
- How does the use of CDK4/6 inhibitors in this space contribute to the total cost of care for breast cancer, and what cost containment strategies can we consider adopting?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sevabertinib for Nonsquamous NSCLC
2
Medicaid Work Requirements Mirror Programs in Georgia, Arkansas: Ciara Zachary, PhD, MPH
3
How Effective and Safe Are GLP-1s for Weight Loss?
4
Epcoritamab With Rituximab Plus Lenalidomide Approved for R/R Follicular Lymphoma in Second Line
5













































